Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Comparison of intra-arterial and manual auscultation of blood pressure during submaximal exercise in humans
Wheatley, Courtney M. , Snyder, Eric M., Johnson, Bruce D., Olson, Thomas P. , Joyner, Michael J.

Mayo Clinic

Applied Physiology, Nutrition, and Metabolism | December 10, 2012 | Volume: 38 | Issue: 5 | Pages: 537-544

10.1139/apnm-2012-0294 | PMID 23668762 Get It

Blood pressure (BP) is a key measure of cardiovascular function, and accurate measurement is important to ensure proper clinical evaluation, diagnosis, and treatment. We compared intra-arterial (direct) and cuff auscultation (manual) measurement techniques at rest and during 2 levels of submaximal constant-load exercise (9 min at 40% and 75% maximum watts). Sixty-four adults (aged 29.0 ± 0.7 years; 48% male; height, 173.7 ± 1.2 cm; mass, 73.0 ± 1.7 kg; body mass index, 24.1 ± 0.4 kg·m−2; body surface area, 1.87 ± 0.03 m2) participated in the study. At rest, low, and moderate intensity, direct measurement demonstrated higher systolic BP (SBP) and diastolic BP (DBP) (bias for SBP: 22, 31, and 27 mm Hg and for DBP: 5, 7, and 17 mm Hg; rest, low-, and moderate-intensity, respectively; p < 0.01). At rest, the correlation and agreement between the 2 methods was modest (SBP: r = 0.56, bias = +22.1 mm Hg; DBP: r = 0.53, bias = +4.9 mm Hg; p < 0.001). There was good correlation and agreement with SBP at low and moderate intensity; however, DBP demonstrated a weaker relationship (SBP: r = 0.74 and 0.74, bias = +30.2 and +26.8 mm Hg; DBP: r = 0.39 and 0.28, bias = +7.1 and +13.4 mm Hg; for low and moderate intensity, respectively; p < 0.001). Further, manual measurement demonstrated a greater slope from rest to moderate exercise for the relationship between pulse pressure (PP) and cardiac output (13.6 ± 0.4 vs 12.3 ± 0.4, p = 0.03). As exercise intensity increases, manual DBP tends to bias low compared with direct DBP, which, when combined with parallel increases in SBP, leads to no differences in PP between methods at moderate exercise. Because PP is used to calculate other cardiovascular parameters (mean arterial pressure, systemic vascular resistance), measurement technique and exercise intensity should be considered when using cardiovascular variables as outcome measures.
Screening for Muir‐Torre Syndrome Using Mismatch Repair Protein Immunohistochemistry of Sebaceous Neoplasms
Roberts, Maegan E. , Riegert‐Johnson, Douglas L. , Thomas, Brittany C. , Thomas, Colleen S. , Krishna, Murli , DiCaudo, David J. , Bridges, Alina G. , Hunt, Katherine S., Rumilla, Kandelaria M., Cappel, Mark A. , Heckman, Michael G. , Roberts, Maegan E

Mayo Clinic

Journal of Genetic Counseling | December 5, 2012 | Volume: 22 | Issue: 3 | Pages: 393-405

10.1007/s10897-012-9552-4 | PMID 23212176 Get It

AbstractScreening for the Muir‐Torre variant of Lynch Syndrome (LS) using Mismatch Repair (MMR) gene immunohistochemistry (IHC) on sebaceous neoplasms (SNs) is technically feasible. To date, research into the clinical utility of MMR IHC for this indication is limited. We conducted a retrospective chart review of 90 patients with MMR IHC completed on at least one SN from January 2005 to May 2010. SNs included were adenomas, epitheliomas, carcinomas and basal and squamous cell carcinomas with sebaceous differentiation. Of the 90 patients, 13 (14 %) had genetically confirmed or fulfilled clinical criteria for a diagnosis of MTS and 51 patients (57 %) presented with an abnormal MMR IHC result (loss of one or more MMR proteins) on at least one SN. Abnormal IHC had a sensitivity of 85 %, specificity of 48 %, positive predictive value (PPV) of 22 % and negative predictive value (NPV) of 95 % when evaluating for MTS. When personal or family history of colorectal cancer (≥2 family members with a history of colorectal cancer) was taken into consideration, ignoring IHC results, sensitivity was 92 %, specificity was 99 %, PPV was 92 % and NPV was 99 %. MMR IHC on SNs when used to screen for MTS has poor diagnostic utility. We recommend that MMR IHC not be performed routinely on SNs when the patient does not have either personal or family history of colorectal cancer.
inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations
Schwind, Sebastian , Edwards, Colin G., Mrózek, Krzysztof , Maharry, Kati , Wu, Yue-Zhong, Paschka, Peter , Eisfeld, Ann‐Kathrin , Hoellerbauer, Pia , Becker, Heiko , Metzeler, Klaus H. , Curfman, John, Kohlschmidt, Jessica, Prior, Thomas W., Kolitz, Jonathan E. , Blum, William , Pettenati, Mark J., Cin, Paola Dal , Carroll, Andrew J. , Larson, Richard A. , Volinia, Stefano , Marcucci, Guido , Bloomfield, Clara D. , Nicolet, Deedra , Caligiuri, Michael A. , Larson, Richard A

Mayo Clinic

Blood | November 17, 2012 | Volume: 121 | Issue: 2 | Pages: 385-391

10.1182/blood-2012-07-442772 | PMID 23160462 Get It

Abstract The inv(16)(p13q22)/t(16;16)(p13;q22) in acute myeloid leukemia results in multiple CBFB-MYH11 fusion transcripts, with type A being most frequent. The biologic and prognostic implications of different fusions are unclear. We analyzed CBFB-MYH11 fusion types in 208 inv(16)/t(16;16) patients with de novo disease, and compared clinical and cytogenetic features and the KIT mutation status between type A (n = 182; 87%) and non–type A (n = 26; 13%) patients. At diagnosis, non–type A patients had lower white blood counts (P = .007), and more often trisomies of chromosomes 8 (P = .01) and 21 (P < .001) and less often trisomy 22 (P = .02). No patient with non–type A fusion carried a KIT mutation, whereas 27% of type A patients did (P = .002). Among the latter, KIT mutations conferred adverse prognosis; clinical outcomes of non–type A and type A patients with wild-type KIT were similar. We also derived a fusion-type–associated global gene-expression profile. Gene Ontology analysis of the differentially expressed genes revealed—among others—an enrichment of up-regulated genes involved in activation of caspase activity, cell differentiation and cell cycle control in non–type A patients. We conclude that non–type A fusions associate with distinctclinical and genetic features, including lack of KIT mutations, and a unique gene-expression profile.
Telomere Length and Pancreatic Cancer: A Case–Control Study
Gangnon, Ronald E. , Johnson, Ruth, Chari, Suresh T. , Petersen, Gloria M. , Boardman, Lisa A., Skinner, Halcyon G. , Litzelman, Kristin , Boardman, Lisa A., Chari, Suresh T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 7, 2012 | Volume: 21 | Issue: 11 | Pages: 2095-2100

10.1158/1055-9965.epi-12-0671 | PMID 23093543 Get It

Abstract Background: Telomeres, the ends of chromosomes, are critical for maintaining genomic stability and grow shorter with age. Shortened telomeres in pancreatic tissue play a key role in the pathogenesis of pancreatic cancer, and shorter telomeres in peripheral blood leukocytes (PBL) have been associated with increased risk for several cancer types. We hypothesized that shorter blood telomeres are associated with higher risk for pancreatic cancer. Methods: Telomere length was measured in PBLs using quantitative real-time PCR in 499 cases with pancreatic cancer and 963 cancer-free controls from the Mayo Clinic. ORs and confidence intervals (CI) were computed using logistic generalized additive models (GAM) adjusting for multiple variables. Results: In multivariable adjusted models, we observed a significant nonlinear association between telomere length in peripheral blood samples and the risk for pancreatic cancer. Risk was lower among those with longer telomeres compared with shorter telomeres across a range from the 1st percentile to 90th percentile of telomere length. There was also some evidence for higher risk among those with telomeres in the longest extreme. Conclusions: Short telomeres in peripheral blood are associated with an increased risk for pancreatic cancer across most of the distribution of length, but extremely long telomeres may also be associated with higher risk. Impact: Although the temporality of this relationship is unknown, telomere length may be useful as either a marker of pancreatic cancer risk or of the presence of undetected pancreatic cancer. If telomere shortening precedes cancer incidence, interventions to preserve telomere length may be an effective strategy to prevent pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 21(11); 2095–100. ©2012 AACR.
Robotic Intracorporeal Urinary Diversion: Ileal Conduit
Johnson, David C. , Castle, Erik P., Pruthi, Raj S. , Woods, Michael E.

Mayo Clinic

Journal of Endourology | October 26, 2012 | Volume: 26 | Issue: 12 | Pages: 1566-1569

10.1089/end.2012.0447 | PMID 23102129 Get It

Subclinical Cardiomyopathy and Long QT Syndrome: An Echocardiographic Observation
Haugaa, Kristina H. , Johnson, Jonathan N. , Bos, J. Martijn , Phillips, Brandon Lane, Eidem, Benjamin W., Ackerman, Michael J. , Bos, Johan M , Haugaa, Kristina

Mayo Clinic

Congenital Heart Disease | October 25, 2012 | Volume: 8 | Issue: 4 | Pages: 352-359

10.1111/chd.12011 | PMID 23095322 Get It

High-Risk Long QT Syndrome Mutations in the Kv7.1 (KCNQ1) Pore Disrupt the Molecular Basis for Rapid K+ Permeation
Burgess, Don E. , Bartos, Daniel C. , Reloj, Allison R., Campbell, Kenneth S. , Johnson, Jonathan N. , Tester, David J. , Ackerman, Michael J. , Fressart, Véronique , Guicheney, Pascale , Moss, Arthur J. , Ohno, Seiko , Horie, Minoru , Delisle, Brian P. , Denjoy, Isabelle , Ohno, Seiko , Horie, Minoru

Mayo Clinic

Biochemistry | October 23, 2012 | Volume: 51 | Issue: 45 | Pages: 9076-9085

10.1021/bi3009449 | PMID 23092362 Get It

Risks and adverse outcomes associated with emergency‐release red blood cell transfusion
Mulay, Sudhanshu , Jaben, Elizabeth A., Johnson, Pamela M. , Badjie, Karafa S., Stubbs, James R.

Mayo Clinic

Transfusion | October 16, 2012 | Volume: 53 | Issue: 7 | Pages: 1416-1420

10.1111/j.1537-2995.2012.03922.x | PMID 23067326 Get It

BackgroundGroup O red blood cell (RBC) units are used for emergency transfusions and are often uncrossmatched when transfused. We sought to determine the risk of alloimmunization and identify acute adverse outcomes of this practice.Study Design and MethodsThe transfusion medicine database was searched for emergency‐release transfusion (ERT) episodes from January 2006 through December 2010. The data collected included age and sex of the recipient, blood bank history, survival after the ERT episode, antibody screen results, antibody identifications, and compatibility of released units.ResultsA total of 1444 ERT episodes took place involving 1407 patients. A total of 4144 RBC units were released. Of the 129 positive antibody screens, 34 had no antibody on further work‐up, 14 had autoantibodies, 48 had a single antibody specificity, and 25 had multiple antibody specificities. Seven patients developed an antibody that could be attributed to the ERT episode, and 15 patients developed an antibody after ERT and additional RBC transfusions. There were 32 reported suspected transfusion reactions. No acute hemolytic transfusion reactions were reported. Seven patients were given a total of 10 incompatible RBC units. Of these patients, one developed a delayed serologic transfusion reaction. The rate of alloimmunization attributable to ERT was 3%. Overall, the rate of incompatible transfusion was less than 0.3% and the rate of a delayed hemolytic transfusion reaction was approximately 0.02%.ConclusionThere is minimal risk associated with the release of emergency uncrossmatched blood in the setting of an acutely bleeding patient. [Correction statement added after online publication 15‐Oct‐2012: the number of patients with autoantibodies, single antibody specificity and multiple antibody specificity has been update.]
Effects of Type 2 Diabetes and Insulin on Whole-Body, Splanchnic, and Leg Protein Metabolism
Short, Kevin R. , Irving, Brian A. , Basu, Ananda , Basu, Rita , Johnson, Christopher M. , Nair, K. Sreekumaran

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 3, 2012 | Volume: 97 | Issue: 12 | Pages: 4733-4741

10.1210/jc.2012-2533 | PMID 23032060 Get It